Nova Biosciences — Internal Technical Dossier

Project Prometheus

CLASSIFICATION: INTERNAL / PATENT-PENDING — NOT FOR PUBLIC RELEASE

This document exists to support Nova Biosciences’ pending device and method-of-use patent filings. It has never been submitted for academic publication and is not to be circulated outside cleared personnel and patent counsel. Where the public record references Nova Biosciences’ anti-aging platform, it should draw only on public interview material — this dossier is the underlying engineering record that material was drawn from, not a source to be cited directly.

1. Executive Summary

Project Prometheus is the internal name for the redesigned TIGR-Tas delivery platform originally developed by Dr. Amelia T. Murphy and Dr. Mark Lee Spencer at Dome 1 (2110), subsequently redirected toward radiation-damage repair at Dome 4 (2118–2122). During extended murine and porcine trials of the radiation-repair configuration, the platform demonstrated a consistent, unplanned secondary effect: measurable telomere elongation and partial reversal of age-associated DNA methylation patterns, independent of and unrelated to its intended radiation-repair function.

Rather than publish these findings, Nova Biosciences elected to file the underlying mechanism as a device and method patent, keeping exact molecular specifications as trade secret beyond what claims require for enforceability. This decision was commercial, not scientific: a public paper would have disclosed the mechanism to any competitor capable of fabricating it, in a market where fabrication capability, not underlying theory, is the actual bottleneck. Nova Biosciences’ approach mirrors, structurally, the same logic behind Cognitive Genesis Research’s 2045 voluntary technical redaction, though for competitive rather than containment reasons.

2. Platform Origin

Project Prometheus is not a new platform but a third-generation payload configuration built on the original TIGR-Tas chassis (see: Murphy & Spencer, 2110, public). The chassis itself — frame, guidance system, sensor suite — is materially unchanged from the published 2110 design. What differs is the payload module, described in Section 3.3 below, which has never appeared in any public disclosure.

3. Technical Specifications

3.1 Chassis and Guidance (unchanged from 2110 public design)

Frame: Protein–DNA hybrid scaffold, fabricated via focused-beam deposition, layer by layer at the nanoscale. Biodegradable; intact units below the renal filtration threshold (~5.5 nm hydrodynamic diameter) clear via normal kidney function once deactivated.
Guidance: External magnetic field steering (embedded iron-oxide domains) for coarse positioning, with acoustic (focused ultrasound) fine positioning for final docking. No onboard propulsion beyond passive circulation and field-responsive steering.
Control logic: Distributed molecular logic via DNA strand-displacement circuits — soft, chemically-implemented decision logic rather than rigid mechanical computation. Sufficient for target recognition and go/no-go actuation; not a general-purpose computer.
Sensor suite: Molecularly imprinted polymer receptors, tuned to exposed beta-sheet conformations characteristic of misfolded proteins (prion aggregates, amyloid-beta, huntingtin).

3.2 Disease Core (TIGR-Tas gene-editing payload, public since 2110)

Dual-guide-dependent gene-editing complex, requiring two simultaneous guide-sequence matches before editing activity is enabled — substantially reducing off-target edit rates relative to single-guide editing platforms. Used once per patient course; edits are permanent by design, appropriate for a one-time correction of a genetic or protein-aggregation disorder.

3.3 Aging Core (Project Prometheus payload — CLASSIFIED, patent-pending)

The Aging Core does not edit the genome. This was a deliberate design constraint: permanent genomic activation of telomerase (hTERT) is a documented hallmark of malignant transformation, present in the substantial majority of human cancers. A platform that permanently switched on telomerase expression across somatic tissue would trade age-related decline for a materially increased cancer risk — an unacceptable trade for a therapy intended for repeated, long-term use.

Instead, the Aging Core delivers a transient, non-integrating countermeasure, cleared from the body between treatment cycles:

Docking clamp: Anchors reversibly to the 3’ single-stranded overhang at the telomere terminus.
Delivery module: Releases a pre-assembled, exogenous telomerase-mimetic ribonucleoprotein complex directly at the docking site — functionally analogous to native telomerase, but delivered as a complete, non-integrating protein-RNA complex rather than expressed from an edited gene. The complex extends the telomere processively while docked, then degrades on a fixed schedule (target: full clearance within 72 hours of administration), after which no telomerase activity remains anywhere in the treated tissue until the next scheduled dose.
Shelterin-stabilizer (secondary/backup mode): Where elongation is not indicated or not tolerated, the module can instead deliver pre-folded shelterin-complex proteins (TRF1, TRF2, POT1 analogues) to physically cap and stabilize existing telomere ends, preventing their recognition as double-strand breaks — the recognition event that normally triggers cellular senescence. This mode extends functional cellular lifespan without altering telomere length at all, and is fully reversible by simply discontinuing dosing.
Length governor: An integrated molecular sensor halts extension once telomere length reaches a pre-set target range, preventing runaway elongation.

Because no permanent genomic change occurs, treatment is inherently titratable and reversible: dosing is administered on an annual or semi-annual schedule rather than as a one-time intervention, and can be discontinued at any time without leaving a permanent genomic alteration behind. This is, internally, understood to be both the platform’s core safety advantage and the basis of its recurring-revenue commercial structure.

4. Safety Profile

No immunogenic response, cytokine cascade, or inflammatory reaction observed in murine or porcine models across the full study window.
No hepatic, renal, or hematologic toxicity observed at therapeutic dosing.
No evidence of oncogenic transformation in any treated cohort, consistent with the non-integrating design of the Aging Core.
Chronic effects beyond the current study window (18 months, porcine) remain unestablished; long-duration human data does not yet exist.

5. Preclinical Efficacy Data

Prion/Huntington’s/Alzheimer’s clearance (Disease Core): Consistent with 2110 published results — complete clearance of pathological aggregates in all treated cohorts.
Telomere elongation (Aging Core, elongation mode): Treated cohorts showed telomeres approximately 20% longer than untreated littermates following a full dosing cycle.
Methylation profile: Partial reversal of age-associated methylation drift observed in treated tissue samples, consistent with reduced biological-age markers on standard epigenetic clock assays.
Lifespan extension (murine): Approximately 30% extension in median lifespan observed in continuously-dosed cohorts relative to untreated controls.

6. Disclosure Strategy

No academic paper covering the Aging Core payload has been or will be published. The patent filing itself discloses only what is required for enforceable device and method claims; exact ribonucleoprotein sequence data, shelterin-analogue formulations, and dosing schedule specifics are retained as trade secret alongside the patent, consistent with standard practice for platforms where the manufacturing capability, not the underlying biological theory, represents the actual competitive barrier.

7. Known Limitations

Manufacturing at scale-appropriate densities for a mass consumer market remains costly relative to Earth-side per-capita healthcare spending; current pricing structure targets high-value niche markets (long-duration space habitation, space hotel guests) rather than general population deployment.
Blood-brain barrier crossing (required for Disease Core deployment) still requires temporary permeabilization; not required for Aging Core, which operates primarily on peripheral tissue.
No data exists beyond 18 months of continuous dosing; long-term safety of indefinite annual/semi-annual redosing over multiple decades is unestablished and will not be known until current long-duration cohorts mature.

Filed with patent counsel, 2122. Distribution restricted to Nova Biosciences cleared personnel and legal counsel only.

Sources

Nova Biosciences internal technical dossier, filed with patent counsel (2122)
Murphy & Spencer, “TIGR-Tas: Targeted Nanoscale Gene-Editing Complex for Prion, Huntington’s, and Amyloid-Associated Neurodegeneration” (2110)

Datastack Archives

Explorer

Nova Biosciences — Internal Technical Dossier: Project Prometheus